If you have been reading about Semax and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-28. Numbers and descriptions here follow the published literature rather than marketing material.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic heptapeptide | Analog of an ACTH fragment |
| Amino acid length | Seven residues | Met-Glu-His-Phe-Pro-Gly-Pro |
| Origin | Moscow, 1980s | Institute of Molecular Genetics |
| Approved regions | Russia and some neighboring states | Not cleared in Western markets |
| Common trade names | Multiple national brands | Sold as a nasal formulation |
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
该化合物于二十世纪八十年代在俄罗斯被开发，相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性，而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示，这一方向促成了多个相关短肽的合成与筛选，而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。
研究兴趣主要集中在神经营养因子相关的路径上，包括脑源性神经营养因子与神经生长因子的表达变化。部分实验报告称在特定条件下观察到这些因子的水平上升，但具体信号通路和剂量依赖关系仍未完全厘清。多数公开数据来自细胞模型和动物实验，人体对照研究数量有限。因此，该化合物的作用机制在文献中属于活跃讨论，而非已经确立的定论。
Major Brian James Dupree, Royal Army Physical Training Corps, Army Reserve, 551069. Major Robert George Fellows, The Rifles, 564703. Major Toby Christian Foster, The Rifles, 30039908. Lieutenant Colonel Christopher Simon Garrard, Corps of Royal Engineers, 24775389. Major Alex Jonathon Glynn, Royal Regiment of Artillery, 30050302. Major Jason Arthur Evan Groves, The Royal Welsh, 24870156. Major Kamal Gurung, The Queen's Gurkha Signals, 21169129. Major Alexander Roy Hamilton, , Corps of Royal Engineers, Army Reserve, 557167. Major Peter Anthony Harrison, , The Royal Logistic Corps, Army Reserve, 24859413. Major Steven Ross Duncan Maguire, The Royal Irish Regiment, 25232971. Bombardier (now Acting Sergeant) Alicia Rhiannon Martin, Royal Regiment of Artillery, 30177630. Major Neil Alexander McClelland, Scots Guards, 24867941. Major Christopher James Patrick Murphy, The Blues and Royals (Royal Horse Guards and 1st Dragoons), 30039546. Corporal Tonderai Ndlela, Adjutant General's Corps (Staff and Personnel Support Branch), 30145012. Lieutenant Colonel Christopher David Newton, Royal Regiment of Artillery, 24826197. Private Ernest Chinazor Okenyi, The Royal Logistic Corps, 30330523. Major Stacy Leanne Oliver, Royal Army Medical Corps, 30133469. Captain Pierre Andrew Ozanne, The Princess of Wales's Royal Regiment/The Ranger Regiment, 30277687. Lieutenant Colonel Daniel Sambrooke Proctor, Corps of Royal Electrical and Mechanical Engineers, 24781852. Staff Sergeant Matthew Francis Robinson, Corps of Royal Engineers, Army Reserve, 25099098.
AMPylation of the IbpA Fic domain of Rho family GTPases is responsible for its cytotoxicity. Both Fic domains have similar effects on host cells' cytoskeleton as VopS. The AMPylation on a tyrosine residue of the switch 1 region blocks the interaction of the GTPases with downstream substrates such as PAK. DrrA is the Dot/Icm type IV translocation system substrate DrrA from Legionella pneumophila. It is the effector secreted by L. pneumophila to modify GTPases of the host cells. This modification increases the survival of bacteria in host cells. DrrA is composed of Rab1b specific guanine nucleotide exchange factor (GEF) domain, a C-terminal lipid binding domain and an N-terminal domain with unclear cytotoxic properties. Research works show that N-terminal and full-length DrrA shows AMPylators activity toward host's Rab1b protein (Ras related protein), which is also the substrate of Rab1b GEF domain. Rab1b protein is the GTPase Rab to regulate vesicle transportation and membrane fusion. The adenylation by bacteria AMPylators prolong GTP-bound state of Rab1b. Thus, the role of effector DrrA is connected toward the benefits of bacteria's vacuoles for their replication during the infection.
On 14 March, an international group of researchers presented a preliminary analysis at a meeting of the World Health Organization's Scientific Advisory Group for Origins of Novel Pathogens, at which Chinese COVID-19 researchers were also present. On the sixteenth, George Gao, the former head of the CCDC and lead author on the February 2022 preprint, told Science that there was "nothing new" in the raw data, and refused to answer questions about why his research team had removed it from the database. On 17 March, the WHO director-general said that the data should have been shared three years earlier, and called on China to be more transparent in its data-sharing. There exists further data from further samples which has not yet been made public. Maria Van Kerkhove, the WHO's COVID-19 technical lead, called for it to be made public immediately (see Huanan live-animal market#Swabs).
Sources: en.wikipedia.org
Morrie reveals he first heard the tune being hummed from the roof, leading Nick to investigate and finding the body of a music shop owner he had met last night. This triggers another vivid vision of the music shop owner being murdered, and Nick wakes back up in the hotel room, this time with a dead woman. Nick comes to believe he murdered Virgil and many other people, and suffers more vivid hallucinations where he is taunted by the infamous serial killer Foggy Jack, who reveals he is the one who murdered Virgil and many of Nick's fans. Nick defeats Foggy Jack and then performs a concert for his fans, promising to change his hedonistic lifestyle. We All Fall Down: The final DLC story is about Arthur's former supervisor, Victoria Byng, who is the daughter of General Robert Byng, a customer of Sally's. After escaping Ollie's custody, Victoria must deal with Joy withdrawal as well as the collapse of law and order in Wellington Wells. She is armed with a whip that she can use to both attack enemies and access higher levels to avoid danger. She also has a dart gun to silently dispatch enemies and disable security defences. After escaping from Ollie and getting her whip, Victoria is able to return to town. However, with the effects of Joy having worn off, she can clearly see that the citizens of Wellington Wells are unknowingly suffering from famine and plague. She also begins seeing visions of her mother, who gives her advice on how to proceed.
== Combination hemoglobinopathies == A combination hemoglobinopathy occurs when someone inherits two different abnormal hemoglobin genes. If these are different versions of the same gene, one having been inherited from each parent it is an example of compound heterozygosity. Some examples of clinically significant combinations involving beta thalassemia include:
adenosine monophosphate (AMP) A nucleoside consisting of adenosine attached to a single phosphate group via a high-energy ester bond. Additional phosphate groups can be added to AMP to produce ADP and ATP; the cyclic ester of AMP serves as a second messenger in some signaling pathways.
Sources: en.wikipedia.org
== Research == Octreotide has also been used off-label for the treatment of severe, refractory diarrhea from other causes. It is used in toxicology for the treatment of prolonged recurrent hypoglycemia after sulfonylurea and possibly meglitinide overdose. It has also been used with varying degrees of success in infants with nesidioblastosis to help decrease insulin hypersecretion. Several clinical trials have demonstrated the effect of octreotide as acute treatment (abortive agent) in cluster headache, where it has been shown that administration of subcutaneous octreotide is effective when compared with placebo. Octreotide has also been investigated in people with pain from chronic pancreatitis. It has been used in the treatment of malignant bowel obstruction. Octreotide may be used in conjunction with midodrine to partially reverse peripheral vasodilation in the hepatorenal syndrome. By increasing systemic vascular resistance, these medications reduce shunting and improve renal perfusion, prolonging survival until definitive treatment with liver transplant. Similarly, octreotide can be used to treat refractory chronic hypotension. While successful treatment has been demonstrated in case reports, larger studies have failed to demonstrate efficacy in treating chylothorax. A small study has shown that octreotide may be effective in the treatment of idiopathic intracranial hypertension.
=== Mechanism of action === Sabizabulin, as an orally available molecule, acts on microtubules, a component of the cytoskeleton. It binds to the colchicine binding site on the beta subunit of tubulin, as well as a novel site on the alpha subunit, and causes both to crosslink, thus depolymerizing microtubules and preventing their polymerization. By preventing mitotic spindle formation, this directly inhibits mitosis of tumor cells and endothelial cells attempting to form new blood vessels to feed them. In parallel, microtubule-mediated trafficking of cellular components (including androgen receptors into the nucleus), thus, a potential anti-androgen agent. The transport of viral particles (including SARS-CoV-2) may also be inhibited. These activities can inhibit viral replication and assembly. Inhibition of tubulin polymerization can also inhibit the release of pro-inflammatory cytokines and disrupt the activities of inflammatory cells.
Artistic Achievement – Hellblade: Senua's Sacrifice Audio Achievement – Hellblade: Senua's Sacrifice Best Game – What Remains of Edith Finch British Game – Hellblade: Senua's Sacrifice Debut Game – Gorogoa Evolving Game – Overwatch Family – Super Mario Odyssey Game Beyond Entertainment – Hellblade: Senua's Sacrifice Game Design – Super Mario Odyssey Game Innovation – The Legend of Zelda: Breath of the Wild Mobile Game – Golf Clash Multiplayer – Divinity: Original Sin II Music – Cuphead Narrative – Night in the Woods Original Property – Horizon Zero Dawn Performer – Melina Juergens (as Senua, Hellblade: Senua's Sacrifice) Special Award: Nolan North
On September 26, 1983, Stanislav Petrov received convincing indications of an American first strike launch against the Soviet Union, but positively identified the warning as a false alarm. Though it is unclear what role Petrov's actions played in preventing a nuclear war during this incident, he has been honored by the United Nations for his actions.
Sources: en.wikipedia.org
It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.
It is registered as a medicine in Russia and has been used clinically there for decades. No regulatory agency in Western Europe or North America has approved it for any indication.
Semax corresponds to the four-to-ten fragment of adrenocorticotropic hormone. Because it omits the first three residues, it lacks the adrenal-stimulating action of the full hormone.
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.